Fig. 1A



pAng2i LC06 LC-lambda
8277 bp
BamHI (1)
Leader
Ang2i LC06 VL
CL lambda
XbaI (722)
BGH pA
P-SV40
HygR
IntronA
P-CMV
ClaI (6715)
AmpR
pUC origin
pAng-2i LC06 HC
5483 bp
HindIII (1)
Leader + Leader intron
Ang2i LC06 VH
XhoI (587)
intron
CH1-IgG1
intron
Hinge
intron
CH2
intron
CH3
EagI (2571)
SV40 pA
AvrII (2723)
P-CMV
ClaI (4797)
AmpR
pUC origin

Fig. 1B



pAng2k LC08 LC-lambda
8283 bp
Bam HI (1)
Leader
Ang2k LC08 VL
CL lambda
Xba I (728)
BGH pA
Intron A
P-CMV
Cla I (6721)
AmpR
pUC origin
P-SV40
HygR
pAng2k LC08 HC
5468 bp
HindIII (1)
P-CMV
Cla I (4782)
Leader + Leader intron
Ang2k LC08 VH
Xho I (572)
intron
CH1-IgG1
intron
Hinge
intron
CH2
intron
CH3
SV40 pA
Avr II (2708)
AmpR
pUC origin

Fig. 2



Angpt2k_LC08
Angpt2i-LC07
Angpt2i-LC06
Reduced
Angpt2k_LC08
Angpt2i-LC07
Angpt2i-LC06
Not reduced
250 kD
150 kD
100 kD
75 kD
50 kD
37 kD
25 kD
20 kD
15 kD
10 kD

Fig. 3




SA-POD
hAng1
Tie-2
Tie-2
h-Fc
h-Fc
SA-POD
biot <hAng-2>
Antagonistic Ab
hAng1
Tie-2
Tie-2
h-Fc
h-Fc
plate

Fig. 4


Ang2k_LC08
1,2
1
0,8
0,6
0,4
0,2
0
1
0,1
0,01




Ang2i_LC06
1,2
1
0,8
0,6
0,4
0,2
0
1
0,1
0,01

Fig. 5


Ang2k_LC08
0,75
0,65
0,55
0,45
0,35
0,25
0,15
0,05
0,01
0,1
1



Ang2i_LC06
0,99
0,97
0,95
0,93
0,91
0,89
0,87
0,85
0,83
0,81
0,01
0,1
1

Fig. 6



ANG2_PZ_COLO205_006
Vehicle
Xolair
ANG2i-LC06 10 mg/kg
Ang2k-LC08 10 mg/kg
Mab536 10 mg/kg
Tumor volume [mm3]
Study Day
0
100
200
300
400
500
600
700
15
20
25
30
35
40
45
50
55

Fig. 7



ANG2_PZ_KPL-4_002
Median tumor volume [mm3]
600
500
400
300
200
100
0
34
39
44
49
54
59
64
Study Day
Vehicle
ANG2i-LC06 10 mg/kg
Ang2k-LC08 10 mg/kg
MAB536 10 mg/kg

Fig. 8




Fig. 9A



Ang2_Pz_Colo205_008
Median values
human DNA [pg/µl]
0,035
0,030
0,025
0,020
0,015
0,010
0,005
0,000
Avastin
Avastin + Ang2i-LC06
Ang2i_LC06

Fig. 9B



Metastasis in lung
Ang2_Pz_KPL-4_002
human DNA [ng/ml]
0,025
0,020
0,015
0,010
0,005
0,000
Vehicle
Xolair
Ang2i_LC06
Ang2i_LC07
Ang2i_LC08

Fig. 10A





Fig. 10B


i
ii
iii
iv
v
% neovascularisation
% ischemia
Relative change (inj/uninj)
Uninjected
Injected
NS
**
***
Human Ig G
ANG2i-LC06
ANG2i-LC08
Avastin
Neovascular
Ischemia
Normal